Year |
Citation |
Score |
2010 |
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depression and Anxiety. 27: 417-25. PMID 20455246 DOI: 10.1002/Da.20695 |
0.241 |
|
2004 |
Crowley WF, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H, Reece EA, Catanese V, Johnson SB, Dobs A, Genel M, Korn A, Reame N, Bonow R, Grebb J, et al. Clinical research in the United States at a crossroads: proposal for a novel public-private partnership to establish a national clinical research enterprise. Jama. 291: 1120-6. PMID 14996782 DOI: 10.1001/Jama.291.9.1120 |
0.205 |
|
2003 |
Sung NS, Crowley WF, Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, ... Grebb J, et al. Central challenges facing the national clinical research enterprise. Jama. 289: 1278-87. PMID 12633190 DOI: 10.1001/Jama.289.10.1278 |
0.229 |
|
1998 |
Gheuens J, Grebb JA. Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders". Journal of Clinical Psychopharmacology. 18: 176-9. PMID 9555606 |
0.262 |
|
1998 |
Schooler NR, Tollefson GD, Tran PV, Gheuens J, Grebb JA. Comments on article by Tran and colleagues, 'double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders' (Multiple letters) [4] Journal of Clinical Psychopharmacology. 18: 174-179. PMID 9555605 DOI: 10.1097/00004714-199804000-00013 |
0.26 |
|
1997 |
Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. International Clinical Psychopharmacology. 12: S3-10. PMID 9352340 DOI: 10.1097/00004850-199705002-00002 |
0.194 |
|
1997 |
Grebb JA. XX Meeting of the Collegium Internationale Psychopharmacologicum (CIMP) and the X World Congress of Psychiatry (WCP): Introduction International Clinical Psychopharmacology. 12: S1. DOI: 10.1097/00004850-199705002-00001 |
0.171 |
|
1991 |
Nordstedt C, Gandy SE, Alafuzoff I, Caporaso GL, Iverfeldt K, Grebb JA, Winblad B, Greengard P. Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment. Proceedings of the National Academy of Sciences of the United States of America. 88: 8910-4. PMID 1924350 DOI: 10.1073/PNAS.88.20.8910 |
0.374 |
|
1990 |
Gandy SE, Grebb JA, Rosen N, Albert KA, Devinsky O, Blumberg H, Anderson N, Cedarbaum JM, Porter RJ, Sedvall G. General assay for phosphoproteins in cerebrospinal fluid: a candidate marker for paraneoplastic cerebellar degeneration. Annals of Neurology. 28: 829-33. PMID 2285268 DOI: 10.1002/Ana.410280616 |
0.337 |
|
1990 |
Grebb JA, Girault JA, Ehrlich M, Greengard P. Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. Journal of Neurochemistry. 55: 204-7. PMID 2192014 DOI: 10.1111/J.1471-4159.1990.Tb08839.X |
0.434 |
|
1990 |
Grebb JA, Greengard P. An analysis of synapsin II, a neuronal phosphoprotein, in postmortem brain tissue from alcoholic and neuropsychiatrically ill adults and medically ill children and young adults. Archives of General Psychiatry. 47: 1149-56. PMID 2147098 DOI: 10.1001/archpsyc.1990.01810240069011 |
0.403 |
|
1989 |
Grebb JA, Browning MD, Valverius P, Borg S, Sedvall G, Greengard P. An analysis of postmortem brain samples from 32 alcoholic and nonalcoholic individuals for protein III, a neuronal phosphoprotein. Alcoholism, Clinical and Experimental Research. 13: 673-9. PMID 2688467 DOI: 10.1111/J.1530-0277.1989.TB00403.X |
0.43 |
|
1987 |
Grebb JA, Shelton RC, Freed WJ. Diltiazem or verapamil prevents haloperidol-induced apomorphine supersensitivity in mice. Journal of Neural Transmission. 68: 241-55. PMID 3559539 DOI: 10.1007/BF02098501 |
0.325 |
|
1987 |
Shelton RC, Grebb JA, Freed WJ. Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644. Brain Research. 402: 399-402. PMID 2435367 DOI: 10.1016/0006-8993(87)90054-0 |
0.337 |
|
1986 |
Grebb JA. Nifedipine and flunarizine block amphetamine-induced behavioral stimulation in mice. Life Sciences. 38: 2375-81. PMID 3724362 DOI: 10.1016/0024-3205(86)90605-3 |
0.285 |
|
1986 |
Grebb JA, Shelton RC, Taylor EH, Bigelow LB. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biological Psychiatry. 21: 691-4. PMID 3518822 DOI: 10.1016/0006-3223(86)90132-0 |
0.381 |
|
1985 |
Grebb JA, Ellsworth KA, Freed WJ. Differences between calcium channel inhibitors in their effects on phencyclidine-induced behavioral stimulation in mice. Pharmacology, Biochemistry, and Behavior. 23: 613-8. PMID 4070337 DOI: 10.1016/0091-3057(85)90426-5 |
0.355 |
|
1985 |
Panza G, Grebb JA, Sanna E, Wright AG, Hanbauer I. Evidence for down-regulation of 3H-nitrendipine recognition sites in mouse brain after long-term treatment with nifedipine or verapamil. Neuropharmacology. 24: 1113-7. PMID 3001573 DOI: 10.1016/0028-3908(85)90200-X |
0.253 |
|
1985 |
Panza G, Grebb JA, Shelton RC, Hanbauer I. Nitrendipine-sensitive Ca2+ channels in mouse brain: Evidence for down-regulation of recognition sites after long-term treatment with nifedipine or verapamil Federation Proceedings. 44: No. 2765. |
0.265 |
|
1984 |
Grebb JA, Yingling CD, Reus VI. Electrophysiologic abnormalities in patients with eating disorders. Comprehensive Psychiatry. 25: 216-24. PMID 6584272 DOI: 10.1016/0010-440X(84)90010-5 |
0.223 |
|
Show low-probability matches. |